Strides Pharma Science Limited

Strides Pharma Science Limited, incorporated in 1990, is a pharmaceutical company headquartered in Bangalore, India. The company is listed on the Bombay Stock Exchange and National Stock Exchange of India Limited. Strides is engaged in the development, manufacture, and marketing of pharmaceutical products for regulated and emerging markets. It has seven manufacturing facilities including four US Food and Drug Administration approved facilities. Strides also has in-house R&D infrastructure in Bengaluru, India.
History.
Strides was founded in 1990 by Arun Kumar as “Strides Pharmaceuticals Private Limited”. Over the years, it has grown through numerous strategic moves to attain its position of today.
Key markets of operations.
North America.
Strides Pharma Inc. is front-end company for Strides's operations in the US.
Strides re-entered the US market in 2015 post the divestment of its Specialty injectables franchisee- Agila to Mylan Inc. Its focus is mainly on niche, low volume, low competition, high technology barrier products built around Modified Releases, soft-gel capsules (SGCs), topicals and liquids. In the Consumer Healthcare space, Strides operate both in Brands as well as Private Labels and its key brands include JointFlex, Vanquish, Pediacare and Fergon. At the end of July 2018, Strides had a portfolio of 100+ filed ANDAs ANDAs with 65+ product approvals.
Africa.
Strides business activities in this continent are driven by the philosophy of “In Africa for Africa” which it bolstered with the acquisition of a WHO-approved facility under Universal Corporations in Kenya. Strides has a significant sales footprint in 40+ African countries with a robust medical field force in Africa that helps extend reach to 30,000 doctors.
UK.
Strides operates in the UK through its step down wholly owned subsidiary Strides Pharma UK Ltd, who have been reliably supplying high-quality generics to Tier 1 & Tier 2 wholesalers in the retail sector as well as the NHS through Commercial Medicines Unit tenders.
Germany, Austria and Switzerland (DACH region).
Strides Pharma Global Pte Ltd has acquired a majority stake in Fairmed Healthcare AG, a Switzerland based company with a portfolio of high‐quality generic products encompassing prescription and over‐the‐counter drugs across several therapeutic segments. Fairmed Healthcare has built a strong franchise of supplying high‐quality Rx and OTC products in key European markets and the acquisition will augment Strides’ footprint in continental Europe with a direct presence in the German speaking markets of Germany, Austria and Switzerland collectively called as DACH region. Strides’ vast international product portfolio and Fairmed Healthcare’s market access in the DACH region is a highly complementary combination to pivot an extensive growth in the coming years. The business will incrementally have access to Strides’ already approved product portfolio for the markets Fairmed operates in with supplies from several of its EU approved facilities. 
Institutional business.
Strides is an approved supplier to institutionally funded aid projects and Global Procurement Agencies like USAID, Global Fund, PEPFAR (The US President's Emergency Plan for AIDS Relief), UNICEF, WHO, Pan American Health Organization (PAHO), United Nations Development Program (UNDP), Population Services International (PSI), Chemeonics, PFSCM, amongst others. Its products are supplied to disease-prone regions in Africa, Asia and Latin America with distribution to several areas.
Manufacturing facilities in India and overseas.
Strides has a global manufacturing footprint with seven production units spread across three continents. Five of its manufacturing facilities cater to regulated markets have key regulatory approvals including USFDA, UK MHRA, TGA, PMDA ANVISA, WHO. The Company also own two dedicated production facilities for the emerging markets at Kenya and Bengaluru, India.
Research and development in Bengaluru, India.
Strides is led and driven by its expertise in Research and Development, visible through its success in creating niche and differentiated products portfolio. Its Global Formulation R&D centre at Bangalore drives high value product delivery via latest technology platforms.